Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Australian Pharmaceutical Industries Limited
ABN 57 000 004	320

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark Smith
Date of last notice	6 September 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change	The registered holder is Mark and Anne Smith Super Fund Pty Ltd as trustee for Mark and Anne Smith SF A/C, of which the Director is a director and beneficial owner. 25 October 2017	
No. of securities held prior to change	Nil	
Class	Fully paid ordinary shares	
Number acquired	30,000	
Number disposed	Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$46,950.00	
No. of securities held after change	30,000 ordinary shares	

⁺ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Nature of change	On-market trade
Example: on-market trade, off-market trade, exercise of options, issue of	
securities under dividend reinvestment plan, participation in buy-back	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to	
which interest related prior to	
change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed	n/a
above traded during a +closed period where prior	
written clearance was required?	
If so, was prior written clearance provided to allow the	
trade to proceed during this period?	
If prior written clearance was provided, on what date	
was this provided?	

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.